congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Oral
T-DXd
SGO 2024 | March 16-18, 2024
Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Biomarker and subgroup analyses from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study
Oral
R-DXd
SGO 2024 | March 16-18, 2024
Raludotatug deruxtecan (R-DXd) monotherapy in patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase 1 study